Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03139916 · ClinicalTrials.gov registry record · Phase 2
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT03139916: Completed Phase 2 study of Glioblastoma, sponsored by Massachusetts General Hospital.
NCT03139916 is a Phase 2 study of Glioblastoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 36 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03139916, a Phase 2 study of Glioblastoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a combination of drugs with radiation as a possible treatment for Glioblastoma. The drugs involved in this study are: * Bavituximab * Temozolomide
Primary Outcome
Overall survival is defined as the time from study entry to death from any cause. OS12 is the percentage of subjects who are alive 12 months after study entry. Data for subjects who are lost to follow up prior to documented death will be counted as deaths at the last assessment date when the subject is known to be alive.
Conditions Studied
Interventions
- DRUG Temozolomide
- RADIATION Radiation
- DRUG Bavituximab
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts general Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 2 |
What the finished NCT03139916 record still lists
NCT03139916 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT03139916 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03139916 about?
NCT03139916 is a clinical study titled "Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma". This research study is studying a combination of drugs with radiation as a possible treatment for Glioblastoma. The drugs involved in this study are: * Bavituximab * Temozolomide
What is the current status of trial NCT03139916?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-09-13. Estimated completion is 2022-08-31.
What conditions does trial NCT03139916 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03139916?
The interventions under investigation include: Temozolomide (DRUG), Radiation (RADIATION), Bavituximab (DRUG).
Who is sponsoring clinical trial NCT03139916?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03139916 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03139916's enrollment target sits among peer trials
36 115th of 199 higher than 83 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI